>

 

Home

Welcome

Mission

Apoptosis

Researcher profiles

Ongoing Projects

Facilities

Events

How to find us

 

 

Contact

  • Email:michael.odwyer@hse.ie
  • Phone: + 353 91 542349                                                      
  • Postal address: Department of Haematology, University Hospital Galway, Newcastle Road, Galway

Career History

  • Professor of Haematology NUIG 2007
  • Consultant Haematologist University Hospital Galway 2002
  • Assistant Professor Leukemia Department , Oregon Health & Sciences University 2002
  • Hematology Fellow, Oregon Health & Sciences University 1998-2001

Research Interests

  • Translational research and drug development in haematological malignancies

Research Overview
My research interests are principally in the development of new therapeutic approaches for the treatment of leukaemia and multiple myeloma.  An important aspect of this is collaboration with basic researchers in the biomedical sciences to help translate advances in the laboratory to the bedside.  Current translational projects include the investigation of the potential role of Cdc7 inhibition in chronic lymphocytic leukaemia (CLL) and myeloma, and the use of BH3 mimetics and TRAIL as apoptosis inducing agents in leukaemia.  I have considerable clinical trial experience which should facilitate successful clinical translation. 

Selection of recent publications:

Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010 Jan;194(1):W91-W103. Review. PubMed PMID: 20028897.    

Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. Cdc7 kinase - a new target for drug development. Eur J Cancer. 2010 Jan;46(1):33-40. Epub . PubMed PMID: 19815406.  

Krawczyk J et al. Clofarabine in the treatment of poor risk acute myeloid leukaemia. Hematol Oncol. 2009 Sep 18. [Epub ahead of print] PubMed PMID: 19768694.  

O'Dwyer M, Atallah E. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol. 2009 Apr;46(2 Suppl 3):S16-21. PubMed PMID: 19621545.    

Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009 Oct;23(10):1698-707. Epub 2009 May 28. Review. PubMed PMID: 19474800.  

Harousseau JL and FIGHT-AML-301 Investigators. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood. 2009 Aug 6;114(6):1166-73. Epub 2009 May 21. PubMed PMID: 19470696.    

Osman H, Murray M, Egan E, O'Dwyer M. Outcome in elderly acute myeloid leukaemia. Ir Med J. 2008 Nov-Dec;101(10):307-10. PubMed PMID: 19205141.  

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M,Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug28;359(9):906-17. PubMed PMID: 18753647.